Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
CTLA4 is a member of the immunoglobulin superfamily and encodes a protein which transmits an inhibitory signal to T cells. Additionally we are shipping CTLA4 Proteins (85) and CTLA4 Kits (47) and many more products for this protein.
Showing 10 out of 451 products:
Human Polyclonal CTLA4 Primary Antibody for EIA, IHC (p) - ABIN951196
Liu, Liang, Gao, Pan, Chen, Wang, Xue, Zhang, Zhang: CTLA4 and CD86 gene polymorphisms and susceptibility to chronic obstructive pulmonary disease. in Human immunology 2010
Show all 5 references for 951196
Rat (Rattus) Monoclonal CTLA4 Primary Antibody for FACS - ABIN119633
Lin, Hünig: Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist. in European journal of immunology 2003
Show all 2 references for 119633
Human Monoclonal CTLA4 Primary Antibody for FACS - ABIN951193
Vijayakrishnan, Slavik, Illés, Greenwald, Rainbow, Greve, Peterson, Hafler, Freeman, Sharpe, Wicker, Kuchroo: An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells. in Immunity 2004
Show all 2 references for 951193
Rat (Rattus) Monoclonal CTLA4 Primary Antibody for FACS - ABIN119630
Elflein, Rodriguez-Palmero, Kerkau, Hünig: Rapid recovery from T lymphopenia by CD28 superagonist therapy. in Blood 2003
Show all 2 references for 119630
Human Polyclonal CTLA4 Primary Antibody for FACS - ABIN4897512
Mandapathil, Hilldorfer, Szczepanski, Czystowska, Szajnik, Ren, Lang, Jackson, Gorelik, Whiteside: Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. in The Journal of biological chemistry 2010
Human Polyclonal CTLA4 Primary Antibody for WB - ABIN1714514
Tamaka, Seike, Hagiwara, Sato, Ohtsu: Histamine suppresses regulatory T cells mediated by TGF-? in murine chronic allergic contact dermatitis. in Experimental dermatology 2015
Mouse (Murine) Monoclonal CTLA4 Primary Antibody for FACS - ABIN4897502
Al-Sadeq, Hamad, Abu-Elteen: Patterns of Expression of Vaginal T-Cell Activation Markers during Estrogen-Maintained Vaginal Candidiasis. in Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2010
Mouse (Murine) Monoclonal CTLA4 Primary Antibody for FACS, Neut - ABIN4900291
Kipnis, Cardon, Avidan, Lewitus, Mordechay, Rolls, Shani, Schwartz: Dopamine, through the extracellular signal-regulated kinase pathway, downregulates CD4+CD25+ regulatory T-cell activity: implications for neurodegeneration. in The Journal of neuroscience : the official journal of the Society for Neuroscience 2004
results are consistent with a complex pathway in which CD28 (show CD28 Antibodies) is the primary driver of Treg proliferation and CTLA-4 functions as the main brake but is also dependent on TCR signals and interactions with CD80 (show CD80 Antibodies)/CD86 (show CD86 Antibodies)
CTLA-4(+) microvesicles can competitively bind B7 costimulatory molecules on bystander dendritic cells, resulting in downregulation of B7 surface expression.
this study shows that miR (show MLXIP Antibodies)-155 is modulated by a major dust mite allergen, Dermatophagoides farinae (Df1), and increases CD4 (show CD4 Antibodies)+ T cell proliferation through the downregulation of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) expression
CTLA-4 regulates atherosclerosis by suppressing proatherogenic immune responses.
Data suggest enhanced clinical benefit from combining CTLA-4 antigen blockade with poxvirus-based active immunotherapy.
up-regulated expression correlates with the tolerogenic effect of syngeneic hematopoietic stem cell transplantation
Induced Treg Cells Augment the Th17-Mediated Intestinal Inflammatory Response in a CTLA4-Dependent Manner
CTLA-4 has a regulatory T cell-intrinsic role in limiting peripheral regulatory T cell expansion and activation, and in their capacity to control conventional T cells.
The Ctla4 SNP (e2_77A/G) does not alter diabetes susceptibility, but does control mRNA alternative splicing.
Sorafenib suppressed the expression of immunosuppressive factors in MDSCs. These data indicate that combination therapy of sorafenib and anti-CTLA-4 Ab may be effective in advanced kidney cancer patients.
For anti-CTLA4 therapy, there were no data retrievable on clinical efficacy. Although data on clinical efficacy of checkpoint inhibitors in metastatic bladder cancer are currently limited, the efficacy of these drugs might depend mainly on the metastatic volume and immune system integrity. Patients with PD-L1 (show CD274 Antibodies) positive tumors and non-visceral metastases seem to derive the highest benefit from therapy.
interpreting the functional significance of mutations in the CTLA-4 pathway identified by gene-sequencing approaches
In multivariable analysis, patients receiving cord blood units with GG-CTLA4 genotype had poorer neutrophil recovery, increased non-relapse mortality, and inferior disease-free survival.
CTLA-4 +49 A/G polymorphism is not associated with Henoch-Schonlein purpura (HSP).
Combined IL-21 (show IL17C Antibodies)-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient
High CTLA4 Circulating Levels are associated with Breast Cancer.
The CTLA4-CD28 (show CD28 Antibodies) gene fusion is likely a major contributor to the pathogenesis of T-cell lymphomas and represents a potential target for anti-CTLA4 cancer immunotherapy.
this study shows that in fresh Tregs the level of soluble CTLA4 is half of that of full-length CTLA4, whereas in expanded cells sCTLA4 level is tenfold lower
findings indicate that CTLA-4 (+49 A/G) and (-318 C/T) genotypes could be considered as genetic risk factors associated with susceptibility or protection for type 2 diabetes.
Suggest a truncated diphtheria toxin based recombinant porcine CTLA-4 fusion toxin as a novel approach for in vivo depletion of CD80 (show CD80 Antibodies)-positive cells.
The surface expression of CTLA-4 was increased in subclinical stages of paratuberculosis infection while levels of ZAP-70 (show ZAP70 Antibodies) were decreased in CD4 (show CD4 Antibodies)+ T cells of both subclinical and clinical animals, indicating a change in T cell phenotype with disease state.
These results suggested that the expression level of CTLA-4 in CD4 (show CD4 Antibodies)-positive T cells has a potentially immunosuppressive function in bovine leukemia infection.
Experimental infection with bovine viral diarrhea virus did not provide evidence ofTreg activation based on expression of FoxP3 (show FOXP3 Antibodies) and CTLA4.
This gene is a member of the immunoglobulin superfamily and encodes a protein which transmits an inhibitory signal to T cells. The protein contains a V domain, a transmembrane domain, and a cytoplasmic tail. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. The membrane-bound isoform functions as a homodimer interconnected by a disulfide bond, while the soluble isoform functions as a monomer. Mutations in this gene have been associated with insulin-dependent diabetes mellitus, Graves disease, Hashimoto thyroiditis, celiac disease, systemic lupus erythematosus, thyroid-associated orbitopathy, and other autoimmune diseases.
cytotoxic T-lymphocyte-associated protein 4 precursor
, CD152 protein
, cytotoxic T-lymphocyte protein 4
, cytotoxic T-lymphocyte protein 4 isoform CTLA4-TM
, cytotoxic T-lymphocyte-associated protein 4
, costimulatory molecule B7 receptor
, cytotoxic T lymphocyte-associated antigen 4
, CD152 antigen
, cytotoxic T-lymphocyte-associated antigen 4
, CD152 isoform
, celiac disease 3
, cytotoxic T lymphocyte associated antigen 4 short spliced form
, cytotoxic T-lymphocyte antigen 4
, cytotoxic T-lymphocyte-associated serine esterase-4
, ligand and transmembrane spliced cytotoxic T lymphocyte associated antigen 4
, soluble form
, transmembrane form
, cytotoxic T lymphocyte-associated protein 4
, costimulatory molecule B7 receptor CD152